Analyst Ratings For Amarin Corporation plc (NASDAQ:AMRN)
Today, HC Wainwright reiterated its Buy rating on Amarin Corporation plc (NASDAQ:AMRN).
There are 5 Buy Ratings, 1 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Amarin Corporation plc (NASDAQ:AMRN) is Buy with a consensus target price of $32.1667 per share, a potential 54.95% upside.
Some recent analyst ratings include
- 4/1/2019-Amarin Corporation plc (NASDAQ:AMRN) had its Buy rating reiterated by HC Wainwright
- 3/21/2019-Amarin Corporation plc (NASDAQ:AMRN) has coverage initiated with a Buy ➝ Buy rating and $27.00 price target
- 1/7/2019-Amarin Corporation plc (NASDAQ:AMRN) had its Buy rating reiterated by SunTrust Banks
- On 3/4/2019 John F Thero, Insider, sold 250,000 with an average share price of $21.31 per share and the total transaction amounting to $5,327,500.00.
- On 3/4/2019 Lars Ekman, Director, sold 135,377 with an average share price of $21.31 per share and the total transaction amounting to $2,884,883.87.
- On 3/1/2019 Michael Wayne Kalb, CFO, sold 100,000 with an average share price of $22.09 per share and the total transaction amounting to $2,209,000.00.
- On 3/1/2019 Steven B Ketchum, Insider, sold 55,543 with an average share price of $21.85 per share and the total transaction amounting to $1,213,614.55.
- On 2/28/2019 Joseph T Kennedy, General Counsel, sold 27,231 with an average share price of $20.72 per share and the total transaction amounting to $564,226.32.
- On 2/22/2019 Kristine Peterson, Director, sold 163,500 with an average share price of $20.02 per share and the total transaction amounting to $3,273,270.00.
- On 2/22/2019 Michael Wayne Kalb, CFO, sold 50,000 with an average share price of $18.97 per share and the total transaction amounting to $948,500.00.
About Amarin Corporation plc (NASDAQ:AMRN)
Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It is also involved in developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. Amarin Corporation plc sells its products principally to wholesalers and specialty pharmacy providers through direct sales force. It has collaboration with Mochida Pharmaceutical Co., Ltd. for the development of EPA-Based drug products and indications. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was founded in 1989 and is headquartered in Dublin, Ireland.
Recent Trading Activity for Amarin Corporation plc (NASDAQ:AMRN)
Shares of Amarin Corporation plc closed the previous trading session at 20,76 up +2,32 12,58 % with 20.9 shares trading hands.